S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases.

S&amp;P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases.

The S&P Pharma Dose – Episode 16: Four Takeaways – Amgen Inc.

S&P Global Ratings Podcast. Tune in for S&P Global Ratings analysts' opinions on trends and events that affect the global markets and your investment decisions. Download the S&P Global Ratings' Podcast to any portable audio device or your desktop. Make the most of your time and stay on top of important business developments around the world. Listen in! Our CreditMatters videos and podcasts provide an easy and informative way to keep up with S&P Global Ratings' global perspective on important credit market developments anytime, anywhere.

Business

S&amp;P Global Ratings Podcast. Tune in for S&amp;P Global Ratings analysts' opinions on trends and events that affect the global markets and your investment decisions. Download the S&amp;P Global Ratings' Podcast to any portable audio device or your desktop. Make the most of your time and stay on top of important business developments around the world. Listen in! Our CreditMatters videos and podcasts provide an easy and informative way to keep up with S&amp;P Global Ratings' global perspective on important credit market developments anytime, anywhere.

Share The S&P Pharma Dose – Episode 16: Four Takeaways – Amgen Inc.

Sign up to save your podcasts

The S&P Pharma Dose – Episode 16: Four Takeaways – Amgen Inc.

The S&P Pharma Dose – Episode 16: Four Takeaways – Amgen Inc.